# Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy

> **NCT03181113** · — · COMPLETED · sponsor: **Xiamen Amoytop Biotech Co., Ltd.** · enrollment: 473 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Peginterferon Alfa-2B
- **DRUG:** Peginterferon Alfa-2A

## Key facts

- **NCT ID:** NCT03181113
- **Lead sponsor:** Xiamen Amoytop Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-18
- **Primary completion:** 2020-09-21
- **Final completion:** 2020-09-21
- **Target enrollment:** 473 (ACTUAL)
- **Last updated:** 2021-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03181113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03181113, "Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03181113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*